Argonaut Manufacturing Services has announced the recent launch of their state-of-the-art aseptic vial filling services. The company worked closely with the Bausch + Ströbel engineering team to design an optimal filling line for biologics.
“As drug substance values continue to rise, we saw a need in the market for fill/finish service providers to adapt. Our line incorporates technologies designed to maximize yield and minimize risk, in order to safeguard every drop of API,” said Chris Duffy, COO of Argonaut. Key line features include robotics, isolator technology, minimal hold up volume, and in-line non-destructive 100% weight checks.
“We are dedicated to supporting our clients in clinical trials and beyond, and we are honored to have our first clients developing the most innovative therapies,” Eric Blair, CCO of Argonaut said. “The ADVANCEDFill technology our line features is ideal in the areas of rare disease, orphan drugs, and other small-batch biologics applications. Personalized medicine is driving an industry need for our services, as we have the ability to provide the small batch throughput and near zero-loss yield needed for precious drug substance.”
“I’m incredibly proud of our team of established industry leaders. Argonaut has designed and built our drug product manufacturing services to meet the demanding requirements of the world’s best biopharma companies,” said Wayne Woodard, CEO of Argonaut. “Our advanced capabilities match the needs for drug product manufacturing today and for decades to come.”
Argonaut will begin serving clinical phase customers in Q1 2020.